Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors
Authors:
- Takuya AzechiTATakuya Azechi
- Yutaka FukayaYFYutaka Fukaya
- Chika NitaniCNChika Nitani
- Junichi HaraJHJunichi Hara
- Hiroshi KawamotoHKHiroshi Kawamoto
- Tomoaki TaguchiTTTomoaki Taguchi
- Kenichi YoshimuraKYKenichi Yoshimura
- Akihiro SatoASAkihiro Sato
- Naoko HattoriNHNaoko Hattori
- Toshikazu UshijimaTUToshikazu Ushijima
- Toshimi KimuraToshimi Kimura
Open Access
- 14 November 2024
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7155-7164
Abstract
Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this study, we aimed to evaluate the pharmacokinetic properties of tamibarotene and construct a precise pharmacokinetic model. We also conducted a non-compartmental analysis and population pharmacokinetic (popPK) analysis based on the results of a phase I study. Targeted pediatric and young adult patients with recurrent or refractory solid tumors were administered tamibarotene at doses of 4, 6, 8, 10, and 12 g/m2/day. Serum tamibarotene concentrations were evaluated after administration, and a popPK model was constructed for tamibarotene using Phoenix NLME. During model construction, we considered the influence of various parameters (weight, height, body surface area, and age) as covariates. Notably, 22 participants were included in this study, and 109 samples were analyzed. A two-compartment model incorporating lag time was selected as the base model. In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP20ck0106421h0003)
This publication has 26 references indexed in Scilit:
- Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human studyCancer Chemotherapy and Pharmacology, 2023
- Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumorsCancer Chemotherapy and Pharmacology, 2021
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- Retinoic acid receptors: From molecular mechanisms to cancer therapyMolecular Aspects of Medicine, 2015
- Pharmacokinetics of single-agent axitinib across multiple solid tumor typesCancer Chemotherapy and Pharmacology, 2014
- Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemiaInternational Journal of Cancer, 2014
- An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinomaHepatology International, 2013
- Neuroblastoma: Biology and stagingCurrent Oncology Reports, 2009
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003
- Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activityJournal of Medicinal Chemistry, 1988